Compare · IRTC vs RMD
IRTC vs RMD
Side-by-side comparison of iRhythm Holdings Inc. (IRTC) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRTC and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.09B, about 9.5x IRTC ($3.50B).
- Over the past year, IRTC is down 37.7% and RMD is down 10.2% - RMD leads by 27.5 points.
- RMD has been more active in the news (9 items in the past 4 weeks vs 6 for IRTC).
- Both have 25 recent analyst ratings on file.
- Company
- iRhythm Holdings Inc.
- ResMed Inc.
- Price
- $109.31+3.22%
- $242.35+2.97%
- Market cap
- $3.50B
- $33.09B
- 1M return
- -2.18%
- +6.16%
- 1Y return
- -37.72%
- -10.21%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 6
- 9
- Recent ratings
- 25
- 25
iRhythm Holdings Inc.
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest IRTC
- iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by iRhythm Holdings Inc.
- iRhythm Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
- iRhythm Provides Update on Cybersecurity Incident Previously Disclosed in June 2026
- iRhythm Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Chief Financial Officer Wilson Daniel G. sold $94,175 worth of shares (773 units at $121.83), decreasing direct ownership by 2% to 34,887 units (SEC Form 4) (tax withholding)
- iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference
- iRhythm Holdings Inc. filed SEC Form 8-K: Leadership Update
- President and CEO Blackford Quentin S. was granted 48,534 shares and sold $3,348,012 worth of shares (26,859 units at $124.65), increasing direct ownership by 11% to 226,008 units (SEC Form 4) (for withholding tax)
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target